Patents by Inventor Allan M. Miller

Allan M. Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OPTIMIZED MESSENGER RNA
    Publication number: 20140350089
    Abstract: The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.
    Type: Application
    Filed: March 3, 2014
    Publication date: November 27, 2014
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Richard F. Selden, Allan M. Miller, Douglas A. Treco
  • OPTIMIZED MESSENGER RNA
    Publication number: 20120252117
    Abstract: The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.
    Type: Application
    Filed: April 12, 2011
    Publication date: October 4, 2012
    Inventors: Richard F Selden, Allan M. Miller, Douglas A. Treco
  • OPTIMIZED MESSENGER RNA
    Publication number: 20100062526
    Abstract: The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.
    Type: Application
    Filed: September 11, 2009
    Publication date: March 11, 2010
    Inventors: Richard F. Selden, Allan M. Miller, Douglas A. Treco
  • OPTIMIZED MESSENGER RNA
    Publication number: 20090148906
    Abstract: The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.
    Type: Application
    Filed: October 26, 2007
    Publication date: June 11, 2009
    Inventors: RICHARD F. SELDEN, ALLAN M. MILLER, DOUGLAS A. TRECO
  • OPTIMIZED MESSENGER RNA
    Publication number: 20090042283
    Abstract: The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.
    Type: Application
    Filed: October 26, 2007
    Publication date: February 12, 2009
    Inventors: Richard F. Selden, Allan M. Miller, Douglas A. Treco
  • OPTIMIZED MESSENGER RNA
    Publication number: 20090017533
    Abstract: The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.
    Type: Application
    Filed: October 26, 2007
    Publication date: January 15, 2009
    Inventors: Richard F. Selden, Allan M. Miller, Douglas A. Treco
  • Optimized messenger RNA
    Patent number: 6924365
    Abstract: The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.
    Type: Grant
    Filed: September 28, 1999
    Date of Patent: August 2, 2005
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Allan M. Miller, Douglas A. Treco, Richard F Selden
  • Library screening method
    Patent number: 5869239
    Abstract: Materials and methods for homologous-recombination screening of DNA libraries constructed in a eukaryotic host and methods for homologous-recombination chromosome walking for isolating overlapping DNA sequences for building an extended physical map of a chromosomal region.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: February 9, 1999
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Douglas A. Treco, Allan M. Miller
  • Method for homologous-recombination screening of recombinant-DNA clones in yeast host libraries
    Patent number: 5783385
    Abstract: Materials and methods for homologous-recombination screening of r-DNA libraries constructed in a yeast host and methods for homologous-recombination chromosome walking for isolating overlapping DNA sequences for building an extended physical map of a chromosomal region.
    Type: Grant
    Filed: September 6, 1994
    Date of Patent: July 21, 1998
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Douglas A. Treco, Allan M. Miller
  • Method of producing a physical map contigous DNA sequences
    Patent number: 5580734
    Abstract: Materials and methods for homologous-recombination screening of DNA libraries constructed in a eukaryotic host and methods for homologous-recombination chromosome walking for isolating overlapping DNA sequences for building an extended physical map of a chromosomal region.
    Type: Grant
    Filed: September 6, 1994
    Date of Patent: December 3, 1996
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Douglas A. Treco, Allan M. Miller
  • Eucaryotic expression vectors
    Patent number: 4925791
    Abstract: A eukaryotic expression vector includes a controllable repressor operator sequence witin the expression control sequence of the vector. The controllable repressor operator sequence represses expression of a heterologous structural gene located downstream of the expression control sequence in the presence of a gene product or a combination of gene products of a yeast mating type locus. This allows control of the expression level of the heterologous structural gene. Controllable repressor operator sequences responsive to the a1/.alpha.2 and .alpha.2 gene products of the MATa and MAT.alpha. yeast mating type locus alleles are described, both derived from genetic material and synthesized chemically.
    Type: Grant
    Filed: March 18, 1986
    Date of Patent: May 15, 1990
    Assignee: Celltech Limited
    Inventors: Kim A. Nasmyth, Allan M. Miller